Ute Massow

913 citations
29 papers · 591 · h-index 8

Impact in

  • Urology top 1%
    • Urinary Bladder and Prostate Research
  • Rheumatology top 2%
    • Pelvic floor disorders treatments
    • Spondyloarthritis Studies and Treatments

Papers in

  • Rheumatology 25
    • Spondyloarthritis Studies and Treatments 20
    • Rheumatoid Arthritis Research and Therapies 12
  • Immunology 17
    • Psoriasis: Treatment and Pathogenesis 14
    • Immunodeficiency and Autoimmune Disorders 3
Co-authors
Cornelia Haag‐Molkenteller (3 shared papers)Marina Brodsky (2 shared papers)Hans-Theo Forst (2 shared papers)Joseph Wang (2 shared papers)Christopher R. Chapple (2 shared papers)Victor W. Νitti (2 shared papers)Philip Van Kerrebroeck (1 shared paper)Andrea Tubaro (1 shared paper)
Journals
Annals of the Rheumatic Diseases (10 papers)RMD Open (5 papers)Lara D. Veeken (3 papers)Blood (2 papers)The Journal of Rheumatology (1 paper)
Partner nations
United StatesGermanyUnited Kingdom

In The Last Decade

Ute Massow

25 papers receiving 579 citations

Peers

Ute Massow
Comparison fields: 5 of 46
  • Urology 399
  • Rheumatology 374
  • Gastroenterology 59
  • Hematology 77
  • Epidemiology 202
Replace H. David Mitcheson with:
H. David Mitcheson United States
G Lijovetzky Israel
Edith Vuillard France
Richard G. Notley United Kingdom
Kathleen Graziano United States
J. Percy Australia
Yavuz Narin Türkiye
Zehra Işık Hasıloğlu Türkiye
M. Ishigooka Japan
Ute Massow relative to H. David Mitcheson United States H. David Mitcheson's profile →
Citations per field
00.5×5×10×15×18×
H. David Mitcheson · 1×
Citations per year

Countries citing papers authored by Ute Massow

Since Specialization
Citations

This map shows the geographic impact of Ute Massow's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ute Massow with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ute Massow more than expected).

Fields of papers citing papers by Ute Massow

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ute Massow. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ute Massow. The network helps show where Ute Massow may publish in the future.

Co-authors

The 25 scholars most cited alongside Ute Massow, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Ute Massow Line = papers co-authored together Ute Massow links everyone, so they are left out of the graph.

All Works

20 of 20 papers shown

Showing the 20 most-cited of 29 papers — load more, or switch the sort, to bring in the rest.

#Work
1
Clinical Efficacy, Safety, and Tolerability of Once-Daily Fesoterodine in Subjects with Overactive Bladder
European Urology ·Christopher R. Chapple, Philip Van Kerrebroeck, Andrea Tubaro, Cornelia Haag‐Molkenteller, Hans-Theo Forst, Ute Massow, Joseph Wang, Marina Brodsky
2007198
2
Efficacy, Safety and Tolerability of Fesoterodine for Overactive Bladder Syndrome
The Journal of Urology ·Victor W. Νitti, Roger R. Dmochowski, Peter K. Sand, Hans-Theo Forst, Cornelia Haag‐Molkenteller, Ute Massow, Joseph Wang, Marina Brodsky, Tamara Bavendam
2007157
3
Phase 2 multiple-dose study of an FcRn inhibitor, rozanolixizumab, in patients with primary immune thrombocytopenia
Blood Advances ·Tadeusz Robak, Maciej Kaźmierczak, Isidro Jarque, Vasile Musteata, Jacek Treliński, Nichola Cooper, Peter Kießling, Ute Massow, Franz Woltering, Rose Snipes, Juan Ke, Grant Langdon, James B. Bussel, Stephen Jolles
202083
4
Validation of Treatment Benefit Scale for Assessing Subjective Outcomes in Treatment of Overactive Bladder
Urology ·Sam Colman, Christopher R. Chapple, Victor W. Νitti, Cornelia Haag‐Molkenteller, Claudia Hastedt, Ute Massow
200861
5
Bimekizumab treatment in patients with active axial spondyloarthritis: 52-week efficacy and safety from the randomised parallel phase 3 BE MOBILE 1 and BE MOBILE 2 studies
Annals of the Rheumatic Diseases ·Xenofon Baraliakos, Atul Deodhar, Désirée van der Heijde, Marina Magrey, Walter P. Maksymowych, Tetsuya Tomita, Huji Xu, Ute Massow, C. Fleurinck, A.M. Ellis, T. Vaux, Julie Shepherd‐Smith, Alexander Marten, Lianne S. Gensler
202325
6
Efficacy, safety and tolerability of rozanolixizumab in patients with chronic inflammatory demyelinating polyradiculoneuropathy: a randomised, subject-blind, investigator-blind, placebo-controlled, phase 2a trial and open-label extension study
Journal of Neurology Neurosurgery & Psychiatry ·Luís Querol, J. de Sèze, Tina Dysgaard, Todd Levine, T Hemanth Rao, Michael H. Rivner, Hans‐Peter Hartung, Peter Kießling, Saori Shimizu, Dominika Marmol, Ali Bozorg, Anny‐Odile Colson, Ute Massow, Filip Eftimov
202412
7
Low uveitis rates in patients with axial spondyloarthritis treated with bimekizumab: pooled results from phase 2b/3 trials
Annals of the Rheumatic Diseases ·Matthew A. Brown, Martín Rudwaleit, F. van Gaalen, Nigil Haroon, Lianne S. Gensler, C. Fleurinck, Alexander Marten, Ute Massow, Natasha de Peyrecave, T. Vaux, Katy White, Atul Deodhar, Irene van der Horst‐Bruinsma
202411
8
Phase II, Multiple-Dose Study of Anti-FcRn Antibody, Rozanolixizumab (UCB7665), in Patients with Primary Immune Thrombocytopenia: Interim Analysis
Blood ·Tadeusz Robak, Isidro Jarque, Vasile Musteata, Peter Kießling, Ute Massow, James Higginson, Rose Snipes, Stephen Jolles
201711
9
Improved physical functioning, sleep, work productivity and overall health-related quality of life with bimekizumab in patients with axial spondyloarthritis: results from two phase 3 studies
RMD Open ·Maureen Dubreuil, Victoria Navarro‐Compán, Annelies Boonen, Karl Gaffney, Lianne S. Gensler, Christine de la Loge, T. Vaux, C. Fleurinck, Ute Massow, V. Taieb, Michael F Mørup, Atul Deodhar, Martín Rudwaleit
20244
10
The Functional Assessment of Chronic Illness Therapy–Fatigue (FACIT-Fatigue) scale in patients with axial spondyloarthritis: psychometric properties and clinically meaningful thresholds for interpretation
Journal of Patient-Reported Outcomes ·David Cella, Christine de la Loge, Fatoumata Fofana, Shien Guo, Alicia M. Ellis, C. Fleurinck, Ute Massow, Maxime Dougados, Victoria Navarro‐Compán, Jessica A. Walsh
20244
11
Rozanolixizumab, an Anti-FcRn Antibody: Final Results from a Phase II, Multiple-Dose Study in Patients with Primary Immune Thrombocytopenia
Blood ·Tadeusz Robak, Maciej Kaźmierczak, Isidro Jarque, Vasile Musteata, Jacek Treliński, Nichola Cooper, Peter Kießling, Ute Massow, Franz Woltering, Rose Snipes, Juan Ke, Grant Langdon, Birgit Haier, James B. Bussel, Stephen Jolles
20194
12
S850 SAFETY AND EFFICACY OF AN ANTI‐FCRN ANTIBODY, ROZANOLIXIZUMAB, IN PATIENTS WITH PRIMARY IMMUNE THROMBOCYTOPENIA: INTERIM RESULTS OF A PHASE II, MULTIPLE‐DOSE STUDY
HemaSphere ·Tadeusz Robak, M Kaźmierczak, Isidro Jarque, Vasile Musteata, Jacek Treliński, Nicholas R. Cooper, Peter Kießling, Ute Massow, Franz Woltering, Rose Snipes, Stephen Jolles
20193
13
POS1104 BIMEKIZUMAB MAINTAINED STRINGENT CLINICAL RESPONSES THROUGH WEEK 52 IN PATIENTS WITH AXIAL SPONDYLOARTHRITIS: RESULTS FROM THE PHASE 3 STUDIES BE MOBILE 1 AND BE MOBILE 2
Annals of the Rheumatic Diseases ·Fabian Proft, Désirée van der Heijde, Xenofon Baraliakos, Joerg Ermann, C. Fleurinck, Ute Massow, Natasha de Peyrecave, V. Taieb, Astrid van Tubergen, Victoria Navarro‐Compán
20232
14
POS0668 LOW UVEITIS RATES IN PATIENTS WITH AXIAL SPONDYLOARTHRITIS TREATED WITH BIMEKIZUMAB: POOLED RESULTS FROM PHASE 2B/3 TRIALS
Martín Rudwaleit, Matthew A. Brown, F. van Gaalen, Nigil Haroon, Lianne S. Gensler, C. Fleurinck, Alexander Marten, Ute Massow, Natasha de Peyrecave, T. Vaux, Katy White, Atul Deodhar, Irene van der Horst‐Bruinsma
20232
15
Long-term safety and sustained efficacy of bimekizumab in patients with ankylosing spondylitis (radiographic axial spondyloarthritis): 5-year results from BE AGILE (phase 2b) and its open-label extension
RMD Open ·Atul Deodhar, Victoria Navarro‐Compán, Denis Poddubnyy, Lianne S. Gensler, Sofía Ramiro, Tetsuya Tomita, Helena Marzo‐Ortega, C. Fleurinck, T. Vaux, Ute Massow, Natasha de Peyrecave, Désirée van der Heijde, Xenofon Baraliakos
20252
16
POS0806 LONG-TERM SUSTAINED EFFICACY AND SAFETY OF BIMEKIZUMAB ACROSS THE FULL SPECTRUM OF AXIAL SPONDYLOARTHRITIS: 2-YEAR RESULTS FROM TWO PHASE 3 STUDIES
Annals of the Rheumatic Diseases ·X. Baraliakos, Ajita Deodhar, D. van der Heijde, F. Van den Bosch, M. Magrey, Walter P. Maksymowych, Tetsuya Tomita, Huji Xu, Ute Massow, C. Fleurinck, T. Vaux, C. Prajapati, Julie Shepherd‐Smith, Alexander Marten, L. S. Gensler
20242
17
POS0215 LONG-TERM SAFETY AND EFFICACY OF BIMEKIZUMAB IN PATIENTS WITH ACTIVE ANKYLOSING SPONDYLITIS: 5-YEAR RESULTS FROM A PHASE 2B STUDY AND ITS OPEN-LABEL EXTENSION
Annals of the Rheumatic Diseases ·Atul Deodhar, V. Navarro-Compán, Denis Poddubnyy, Lianne S. Gensler, Sofía Ramiro, T. Tomita, Helena Marzo‐Ortega, C. Fleurinck, T. Vaux, Ute Massow, D. van der Heijde, Xenofon Baraliakos
20242
18
Long-term safety and efficacy of bimekizumab in axial spondyloarthritis: 2-year results from two phase 3 studies
Lara D. Veeken ·Xenofon Baraliakos, Atul Deodhar, Désirée van der Heijde, Filip Van den Bosch, Marina Magrey, Walter P. Maksymowych, Tetsuya Tomita, Huji Xu, Ute Massow, T. Vaux, C. Prajapati, Myriam Manente, Alexander Marten, Lianne S. Gensler
20251
19
Association of clinical response criteria and disease activity levels with axial spondyloarthritis core domains: results from two phase 3 randomised studies, BE MOBILE 1 and 2
RMD Open ·Victoria Navarro‐Compán, Sofía Ramiro, Atul Deodhar, Philip J. Mease, Martín Rudwaleit, Christine de la Loge, C. Fleurinck, V. Taieb, Michael F Mørup, Ute Massow, Jonathan Kay, Marina Magrey
20241
20
P163 Low uveitis rates in patients with axial spondyloarthritis treated with bimekizumab: pooled results from phase 2b/3 trials
Lara D. Veeken ·Martín Rudwaleit, Matthew Brown, Floris Alexander van Gaalen, Nigil Haroon, Lianne S. Gensler, C. Fleurinck, Alexander Marten, Ute Massow, Natasha de Peyrecave, T. Vaux, Katy White, Atul Deodhar, Dennis McGonagle, Irene van der Horst‐Bruinsma
20241

About Ute Massow

Ute Massow is a scholar working on Rheumatology, Immunology, Hematology, Pathology and Forensic Medicine and Urology, having authored 29 papers that have together received 591 indexed citations. Recurring topics across this work include Spondyloarthritis Studies and Treatments (20 papers), Psoriasis: Treatment and Pathogenesis (14 papers), Rheumatoid Arthritis Research and Therapies (12 papers), Platelet Disorders and Treatments (4 papers), Autoimmune and Inflammatory Disorders Research (4 papers), Urinary Bladder and Prostate Research (3 papers), Immunodeficiency and Autoimmune Disorders (3 papers) and Monoclonal and Polyclonal Antibodies Research (3 papers). The work is most often cited by research in Urology (399 citations), Rheumatology (374 citations), Gastroenterology (59 citations), Hematology (77 citations) and Epidemiology (202 citations). Ute Massow has collaborated with scholars based in United States, Germany and United Kingdom. Frequent co-authors include Cornelia Haag‐Molkenteller, Marina Brodsky, Hans-Theo Forst, Joseph Wang, Christopher R. Chapple, Victor W. Νitti, Philip Van Kerrebroeck, Andrea Tubaro, Tamara Bavendam and Roger R. Dmochowski. Their work appears in journals such as Annals of the Rheumatic Diseases, RMD Open, Lara D. Veeken, Blood and The Journal of Rheumatology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by H. David MitchesonBreakdown of academic impact, for papers by G LijovetzkyBreakdown of academic impact, for papers by Edith VuillardBreakdown of academic impact, for papers by Richard G. NotleyBreakdown of academic impact, for papers by Kathleen GrazianoBreakdown of academic impact, for papers by J. PercyBreakdown of academic impact, for papers by Yavuz NarinBreakdown of academic impact, for papers by Zehra Işık HasıloğluBreakdown of academic impact, for papers by M. Ishigooka